Alector (NASDAQ:ALEC – Get Rating) released its earnings results on Thursday. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.59, Fidelity Earnings reports. Alector had a return on equity of 12.03% and a net margin of 12.06%.
Alector Price Performance
Shares of NASDAQ:ALEC opened at $13.06 on Friday. Alector has a 1 year low of $7.50 and a 1 year high of $29.30. The company has a market cap of $1.09 billion, a PE ratio of 33.49 and a beta of 1.08. The stock’s 50-day moving average is $10.19 and its 200 day moving average is $12.15.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on ALEC shares. Barclays lowered their target price on Alector from $42.00 to $14.00 in a research note on Wednesday, May 11th. Mizuho began coverage on Alector in a research note on Wednesday, July 6th. They issued a “buy” rating and a $15.00 target price for the company. Citigroup reduced their price target on Alector from $34.00 to $19.00 and set a “buy” rating on the stock in a report on Monday, July 11th. Finally, The Goldman Sachs Group reduced their price target on Alector from $9.00 to $6.00 and set a “sell” rating on the stock in a report on Tuesday, May 24th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $20.86.
Institutional Inflows and Outflows
Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.
- Get a free copy of the StockNews.com research report on Alector (ALEC)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Alector Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alector and related companies with MarketBeat.com's FREE daily email newsletter.